Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain

Thrombocytopenia and thrombosis following treatment with the integrin αIIbβ3 antagonist eptifibatide are rare complications caused by patient antibodies specific for ligand-occupied αIIbβ3. Whether such antibodies induce platelet clearance by simple opsonization, by inducing mild platelet activation...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gao, Cunji, Boylan, Brian, Bougie, Dan, Gill, Joan C., Birenbaum, Jessica, Newman, Debra K., Aster, Richard H., Newman, Peter J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2009
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2648674/
https://ncbi.nlm.nih.gov/pubmed/19197137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI36745
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky